NorthStrive Biotherapeutics

Executive Summary

NorthStrive Biotherapeutics is a clinical-stage biopharmaceutical company addressing the critical unmet need of muscle loss during obesity treatment. Founded in 2021 and headquartered in Cambridge, Massachusetts, the company is a subsidiary of PMGC Holdings. Its lead candidate, EL-22, is an orally administered engineered probiotic designed to inhibit myostatin, a negative regulator of muscle growth, thereby preserving lean muscle mass when used in combination with GLP-1 receptor agonists. This approach is particularly relevant as GLP-1 drugs (e.g., semaglutide) cause significant weight loss but also reduce muscle mass, which can lead to sarcopenia and metabolic rebound. NorthStrive's technology aims to differentiate by enabling healthier weight loss with improved body composition. The company is currently in Phase 1 clinical development for EL-22. The initial studies focus on evaluating safety, tolerability, and pharmacokinetics in healthy volunteers, with plans to advance into combination trials with GLP-1 therapies. NorthStrive's probiotic platform leverages engineered strains to produce therapeutic proteins locally in the gut, offering convenient oral delivery and potentially reduced systemic side effects. If successful, EL-22 could become an important adjunct to the growing GLP-1 market, projected to exceed $100 billion by 2030. With a novel mechanism targeting myostatin via an oral probiotic, NorthStrive has a unique value proposition in the obesity space.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 1b combination trial with GLP-1 agonist80% success
• Q4 2026Topline safety and tolerability data from Phase 1 single-ascending dose study70% success
• H2 2026Strategic partnership with a major GLP-1 manufacturer for co-development50% success